Novo adds new U.S. chief amid sales decline
Source: SeekingAlpha
2026-02-04 11:11:20 ET
More on Novo Nordisk A/S
- Novo Nordisk A/S 2025 Q4 - Results - Earnings Call Presentation
- Novo Nordisk: Compressing Margins And Collapsing Guidance Confirm Sell Thesis
- Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
- Novo Nordisk board proposes DKK 7.95 final dividend for 2025, initiates DKK 15B buyback
- Novo Nordisk’s 2026 outlook in focus as competition pressures sales
Read the full article on Seeking Alpha
For further details see:
Novo adds new U.S. chief amid sales decline
Merck KGAA
NASDAQ: MKGAF
MKGAF Trading
-7.08% G/L:
$122.316 Last:
673 Volume:
$124.224 Open:
MKGAF Latest News
July 22, 2025 09:00:00 pm
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support
